Disclaimer: Due to limited levels, errors are inevitable, or some information is not the most timely, welcome to point out.This article is introduced only for medical and health -related drugs, and non -treatment schemes are recommended (if they are involved); this article does not constitute any investment advice.

The field of antibodies-Drug Puppets (ADC) witnessed the diversification of puppet technology, connecting sub-chemistry, and effective loads used, surpassing traditional microtubin inhibitors, including a new mechanism.With a large amount of financing and acquisition, investment in ADC research continues to grow.

In addition, the regional expansion of the market, especially in India, reflects the global promotion of innovative cancer therapy, which can be seen from multiple cooperation and license agreements that aims to bring new ADCs to clinical clinical.Here are some major biotechnology companies in the field of ADC.

Albervi/Immunogen

Abervis has strengthened the company's influence in the field of ADC cancer, especially the physical tumor sector, for $ 10.1 billion.The acquisition includes the flagship cancer therapy (Mirvetuximab Soravtansine-GYNX), which is used in the flagship cancer of IMMUNOGEN for platinum-resistant ovarian cancer.Oncology product line.Immunogen's product portfolio, including the next-generation ADC, such as IMGN-151 for ovarian cancer and Pivekimab Sunrine for rare blood cancer, enhance Albervi's research capabilities and product supply in the field of oncology.

The acquisition not only accelerates the pace of Albervi's entry into the ADC market, but also a key step in its major progress strategy in the field of physical tumor treatment.Elahere is the first drug to show the benefit of overall survival in platinum -resistant ovarian cancer. It successfully provides Albervis with a unique opportunity to lead in the ADC field and further develop innovative cancer treatment methods.

In addition to the acquisition of Immunogen, ABV's ADC pipeline also includes early development projects, such as ABBV-400, a C-MET (mesenchymal transliteration factor) ADC for solid tumors, and two anti-SEZ6 (epilepsy-related with epilepsy (epilepsy (epilepsy (epilepsy (epilepsy (epilepsy (epilepsy (epilepsy (epilepsy (epilepsy (epilepsy (epilepsy related6 homologous) ADC, ABBV-011 and ABBV-706, aiming to solve various cancer indications.

Adcendo

Established in 2017, ADcendo is a spin -off company of Copenhagen University and Rigshospitalet.The Biotechnology Company, located in Copenhagen, used the new target UPARAP receptor discovered by its scientific founders to develop ADCs aimed at improving cancer treatment results.

The UPARAP receptor, also known as Endo180, plays a key role in the management of extracellular matrix of the human body, especially in collagen reshaping.It is essential for tissue repair and maintenance, but it also plays an important role in the progress of cancer because it is overly expressed in several types of cancer types.

ADcendo has cooperated with Australian immune tumor company Glytherix to promote the development of ADCs that targeted GPC-1 (a protein related to multiple physical tumor types).The cooperation aims to use Glytherix's Miltuximab (a leading anti -GPC -1 monoclonal antibody) to further promote the mission of ADCENDO to push innovative treatment plans to the market.

Recently, ADcendo and Duality Biology reached an option license agreement.This protocol is part of the ADC product line strategy to further develop its ADC product line strategy. The product line focuses on creating therapy for various types of cancer.The purpose of this cooperation is to use the ability of Duality Biology to potentially enhance the existing ADC technology of ADcendo.This cooperative relationship reflects ADCENDO's new ways to explore the development of ADC, which aims to expand the scope and effectiveness of its cancer treatment.

ADCENDO received a round A financing of $ 55 million (51 million euros) in 2021 and an additional financing of $ 33 million (31 million euros) in 2023. ADCENDO is in a favorable position and can continue its pioneering in the field of ADC.Sexual work.

Adcentrx therapeutics

Adcentrx is establishing an internal pipeline of innovation ADC to solve the current limitation and challenges in this field.Adcentrx has recently received $ 38 million in A +round of financing, and later added $ 13 million.After the financing of $ 50 million in round A financing in 2021, it marked an important step in the clinical development of its ADC oncology product line.

ADRX-0706, the main candidate product of AdcentRX, is a kind of adc for Nectin-4. Nectin-4 is a cell surface that is excessively expressed in human cancer.This targeted strategy is part of ADCENTRX using a more stable connector technology and using the "onlooker effect" to more accurately transporting effective loads to tumor, thereby improving the efficacy while minimizing side effects.The company plans to promote at least one other pipeline projects to enter the clinical test each year, which indicates that the project is under development.ADRX-0706 obtained the FDA new drug research application approval in July 2023.

In addition to ADRX-0706, adcentrx is studying the second candidate drugs for tumor science indications, and another candidate drug that is aimed at treating immunohistological diseases.The company also reached a three -year partnership with AvantGen in February 2022 to jointly develop antibodies used for new ADCs to expand its product line and solve the needs of cancer and other patients with severe diseases.

ALENTIS Therapeutics

ALENTIS Therapeutics is a clinical biotechnology company that specializes in the development of ADC for Claudin-positive organ fibrosis and cancer.The company's R & D pipeline focuses on anti -CLAUDIN -1 antibodies as a new type of treatment for the treatment of CLDN1 positive tumors and organ fibrosis.ALENTIS is promoting two leading monoclonal antibodies through clinical development, and is also studying the next generation of anti -CLDN1 therapy, including ADC, bilateral antibodies and T cell connectors.

ALENTIS has attracted much attention for its innovative work, and it completed $ 105 million in Series C financing of 105 million US dollars in April 2023.This fund is used to support its main research product ALE's 2nd and 1 -phase project F02 and ALE, and has developed C04 and its CLDN1 platforms.

ALENTIS reported on the positive backline of multiple incremental dosage (MAD) parts in its first clinical study of Ale.F02 confirms that the drug has good safety, exposure and targeted biological activity.In addition, the company has launched the first two -stage test of the first Ale patient.F02 is used for ANCA -related vasculitis with an acute advanced glomerular nephritis (RPGN).This experiment is of great significance because it studies the safety and tolerance of the drug, and the possibility of renal the renal function when it is known to cause rapid renal failure.LIXUDEBART targeted Claudin-1 (CLDN1) may prevent and reverse fibrosis, marking a new method for treating severe kidney disease.

ARARIS BIOTECH

Araris Biotech Ag has made significant progress in the ADC field. Recently, investment from Samsung Ventures is the highlight of it.This fund supports the development of ARARIS's ADC pipeline. This pipeline focuses on cancer treatment and adopts innovative connection technology to simplify development and improve the efficacy of drugs.

The company has also successfully raised $ 24 million to promote its ADC connection sub -technology and push its ADC candidate drugs (such as the highly prospective anti -CD79B) to the clinical stage.Anti -CD79B ADC showed positive results in preclinical studies, showing the potential advantages of existing therapy.

At the AACR annual meeting in 2023, Araris showed two preclinical data for the two ADCs created with its proprietary connecting sub -technology.Compared with the approved ADC, these targeting anti-Nectin-4 and anti-HER2 ADC shows excellent anti-tumor activity and stability, which indicates that ARARIS has more effective development, safer development, lower pharmaceutical loadsThe potential of ADC.

Astrikan/First and Three Communists

Astraco and the first and third have carried out important cooperation in the field of ADC, focusing on the development and commercialization of DS-1062. DS-1062 is an ADC that targeted Trop2 (nourishing layer cell surface antigen 2).This cooperation highlights the potential of various tumor types of DS-1062 using the first and third proprietary DXD ADC technology, including non-small cell lung cancer (NSCLC) and tri-negative breast cancer (TNBC).The partnership enables Astraikon and the first and third to share development, commercial costs and profits, but except in Japan, the first three reserved Japan's exclusive rights.

In addition, the lung cancer research foundation (LCRF) announced a new research cooperation with the first and third Republic of Astraikon, which aims to fund up to three research funding for ADC to improve the prognosis of patients with lung cancer.The plan is designed to explore the potential of ADC in the treatment of lung cancer. It pays special attention to HER2-oriented and Trop2-oriented ADC, including DS-1062 to study its mechanism, biomarkers and drug resistance mechanisms.Jaipur Wealth Management

The strategic cooperation was established after the preliminary cooperation on Her2 -oriented DXD ADC Enhertu.ENHERTU was approved by FDA in 2022 to treat non -small cell lung cancer (NSCLC) adult patients with specific HER2 mutations.The approval is based on the results of Destiny-LUNG02 research. The study shows that ENHERTU significantly reduces the tumor of most patients and provides new treatment options for specific lung cancer patients.

The ADC product line of the first and three Communists is widely, including various candidate drugs for different antigen and cancer.The forefront is the Patritumab Deruxtecan (HER3-DXD) of the EGFR mutation (epidermal growth factor receptor) and the Datopotamab Deruxtecan (DATO-DXD) for the treatment of NSCLC.

The first and third conferences of the DXD ADC product portfolio were displayed at important conferences such as ESMO ASIA and SABCS, and the depth of its oncology product portfolio was displayed.This includes the research of Datopotamab Deruxtecan and HER2 mutant NSCLC in NSCLC with operating genome changes. It shows the research on the first and third co -operating research to promote cancer treatment through ADC.

Both companies are key participants in the field of ADC. Astraikon uses cooperation to enhance its oncology product line, while the first and third a Communist focuses on its proprietary DXD technology to develop major in cancer treatment.ADC that affects.

Biontech/dualitybio

Biontech cooperates with Duality Biology and has always focused on the development of ADC therapy for cancer and autoimmune diseases.Their famous ADC candidate drug BNT323/DB-1303 is currently undergoing a key 3-stage test for patients with metastatic breast cancer.This test is based on the positive safety and effective data of early studies of the early phase of the period. These data indicate that hopeful anti -tumor activity, especially among HER2 low breast cancer patients who have previously received a lot of treatment.The observed objective relief rate and disease control rate are encouraged, highlighting the potential for the prognosis of BNT323/DB-1303 to improve patients with advanced physical tumors.

In addition, BNT323/DB-1303 has obtained a breakthrough therapy for FDA to treat late endometrial cancer.

This cooperation is expected to accelerate these innovative therapies to global patients. Biontech has global commercial rights other than India, Hong Kong and Macau, while Dualitybio retains the rights of these areas.

Beltay Schimi Bao

Through the strategic cooperation aimed at enhanced its tumor product portfolio, Brethrumi (BMS) has significantly strengthened its position in the ADC market.One of the noticeable partnerships is Systimmune, which involves the joint development and commercialization of the EGFRXHER3 dual-specific ADC BL-B01D1, with a transaction value of $ 8.4 billion.

In another strategic move, BMS and Tubulis reached an agreement worth $ 1 billion, using Tubulis's exclusive P5 puppet platform, a new type of chemical reagent and "" new chemical reagent and "Tubutecan "effective load to develop ADC for physical tumors.This cooperation involves not only paying 22.75 million US dollars to Tubulis, but also includes potential development, regulatory and commercial milestones, and the franchise fees for listed products.The alliance aims to generate the only matching ADC for each antibody target, and BMS is fully responsible for its subsequent development, manufacturing and commercialization.

BMS also acquired a phase 1 blood cancer drug from ORUM Therapeutics at a price of $ 100 million, thereby expanding its influence in the ADC field.ORM-6151 with problems is a first-class anti-CD33 (Salmonic acid combined with IG-like condensate 3) GSPT1 degradant with antibody-driven.Success is likely to get a milestone payment of $ 80 million.

These cooperation represents the company's method of expanding its ADC product line, and uses innovative technology to develop cancer therapy.

GlaxoSmithg (GSK) also actively expand its tumor product portfolio through strategic acquisitions and partnerships, especially in the ADC field.A recently noticeable progress is that GSK paid Hansoh Pharma's $ 185 million in prepaid to get the right of HS-20093. HS-20093 is an ADC that targeted B7-H3.Many protein expressed in different cancers in lung cancer.ADC has shown early signs of clinical activity in solid tumors (especially small cell lung cancer and sarcoma), and will begin clinical trials in phase 1 in the region outside India in 2024.Lucknow Stock

In addition, the company has reached another major transaction involving ADCs that targeted B7-H4, called HS-20089, which indicates that GSK is rich in protein to target various cancers (including ovarian cancer and endometrial cancer).ADC has strategic interest.This moves major participants such as GSK and Pfizer in a competitive state in developing effective treatment for these cancers.

Recently, the Dreamm-7-III test showed that GSK's BlenRep (Blandamab Mafodotin) combined with boradisami and groundyamone for the treatment of recurrence/refractory multi-myeloma has improved significantly.Compared with standard nursing combinations, this combination has almost doubled the mid -level no progressive survival period, showing that the risk of disease progress or death is reduced by 59%.The test also shows that the total benefit of the overall survival is a strong trend, and the risk of death has decreased by 43%.These discoveries highlight the potential of BLENRP's treatment strategies for multiple osteoma treatment strategies at the first recurrence or afterwards.

Mbrace

This biotechnology company is actively committed to the ADC field, focusing on MBRC-101, which is aimed at EPHA5 (type protein A type A receptor 5) receptor tyrosine kinase.The significance of targeting EPHA5 is that it is common in a variety of solid tumors, such as triple -negative breast cancer (TNBC) and non -small cell lung cancer (NSCLC), making it an important target for ADC development.

The basis of MBRC-101 is the ability to particularly target EPHA5 (a membrane-related tyrosine kinase receptor).This specificity is essential for the treatment of cancer, because compared with normal cells, the expression differences of EPHA5 in tumor cells provide a way for selective cancer cell targeting and treatment.The MBRC-101 uses the humanized antibody EPHA5 IgG1 antibody with a single-based Auristatin E (MMAE). MMAE is an effective cytotoxic agent.After combining EPHA5 on the cancer cells, the MBRC-101 is internalized, and the MMAE is delivered directly to the cancer cells to induce cell death.Kanpur Investment

The pre-clinical data of MBRC-101 is convincing and shows significant curative effects in the breast cancer model.It has shown an exclusive combination with EPHA5, rapid internalization, and cytotoxicity to cells that express EPHA5.Among the patient's TNBC heterogeneous transparent mouse model, MBRC-101 shows the dosage, stable and repeated anti-tumor activity, providing a strong basis for its clinical development.It is worth noting that the MBRC-101 has good tolerance in different doses in the clinical model. The result of the poisonous science is attributed to the effective load of MMAE, not the target itself.

MBrace Therapeutics is currently promoting MBRC-101 through phase 1/1b clinical trials to determine the best biology-related dose and evaluate the safety and initial activity of MBRC-101 in TNBC, NSCLC and other physical tumors.

In terms of finance, MBrace Therapeutics recently raised $ 85 million in round B financing to further develop its oncology product line.

Oxford Biotherapeutic (OBT) one of the leading ADC OBT076 targeted CD205 receptor, which is expressed in a series of solid tumors and liquid tumors.This innovative method aims to treat the head and neck gland -like cystic cancer (ACC), which is a rare type of invasive cancer.OBT cooperates with Gortec to conduct a 1B-phase test, using OBT076 as a single therapy and PD-1 (programming cell death protein 1) blocking the antibody BalStilimab.This experiment is noticeable because it focuses on the treatment of limited cancer.

In addition, the cooperation between OBT and Boehringer Ingelheim has contributed to the development of BI 764532. This is a research T cell junction that targeted DLL3 (Delta sample 3).protein.Such partnerships have obtained important milestones, including obtaining a fast channel qualification of the US FDA to treat advanced or metastatic pulmonary nerve endocrine cancer (LCNEC-LUNG).

OBT's ADC development work is based on the OGAP platform (cancer -specific membrane protein library), which helps to identify the new and high -specific antigen of cancer targets.This extensive database supports OBT development strategy based on ADC.

Pfizer/Seagen

Pfizer completed the acquisition of Seagen on December 14, 2023, worth about $ 43 billion, marking a major expansion of Pfizer's abilities.This strategic measure has further established Pfizer's position as the leading company in the field of oncology, and accelerate the development of the next generation of cancer treatment.The acquisition combines SEAGEN's pioneering ADC technology with Pfizer's extensive ability and professional knowledge.

SEAGEN's investment portfolio includes four approved cancer therapy, and the total sales of 2022 are close to $ 2 billion.The acquisition not only adds important value to Pfizer's tumor product portfolio, including more than 25 approved drugs and biotechnology drugs, covering more than 40 indications, but also made Pfizer's tumor product line up and reached to reach it to reach60 projects.These projects cover a variety of modes, including ADC, small molecules, bilateral, and other immunotherapy, which is expected to have a wide range of influence on various types of cancer.

One of Seagen's most advanced and most famous ADC is Tivdak (Tisotumab Vedotin-TFTV), which has been approved by FDA to treat recurrence or metastatic cervical cancer in the treatment of chemotherapy.Tivdak represents a major progress of cervical cancer treatment, marking the first ADC approved for the indication.This is ADC approved by the regulatory authorities in Seagen, which is approved by the regulatory authority, showing the company's leadership and innovation ability in the ADC field.

In addition to Tivdak, Seagen also participated in the development of other new ADCs, including SGN-B7H4V, which is targeted at the T cell examination point ligand B7-H4 expressed in various physical malignant tumors.

One of the famous ADCs of Roche is Kadcyla (Telkuzumab Emtansine), which aims to provide effective chemotherapy directly to Her2 -positive cancer cells.KADCYLA has been approved in more than 100 countries/regions including the United States and the European Union to treat HER2 -positive breast cancer patients who have previously received Her2 -positive breast cancer who have accepted Herpatin and atrvane chemotherapy.It is also approved for new assisted therapy (including chemotherapy based on Herceptin and atrvispane drugs). HER2 positive early breast cancer is therapy for residual influential diseases.

Another important ADC developed by Roche is Polivy (POLATUZUMAB VEDOTIN)Varanasi Wealth Management. This is an anti-CD79B antibody-drug puppet combined with the combination of approval with bentamodimettine Galite.It is used to treat adults who are not suitable for recurrence or refractory pervasor B -cell lymphoma that is not suitable for hematopoietic stem cell transplantation.

Roche also promotes ADC technology and cancer treatment through strategic partnerships and investment.For example, Roche has reached important cooperation with Moma Therapeutics to invest more than $ 2 billion for the development of precision cancer drugs.This transaction highlights Roche's strategy, that is, using external professional knowledge and platform to determine new drug targets related to cancer cell growth and survival to develop the next -generation precise drugs.

Another cooperation is to cooperate with MediLink Therapeutics to develop YL211, which is a next -generation ADC for physical tumors.MediLINK uses its proprietary tumor microenviper to activate LINKER-PAYLOAD (Tmalin) ADC technology platform to introduce partnerships, focusing on the target of the C-Metskin Transformation Factor (C-MET) as the target.

Roche will have the exclusive international rights of development, production and marketing YL211 to further consolidate its position in the field of ADC and oncology.The agreement includes paying a total of $ 50 million in prepaid and recent milestones to pay for Medilink, potential development, supervision and commercial milestones up to 1 billion US dollars, as well as the franchise fee for future product sales.

Takeda Pharmaceutical has been actively participating in the development and commercialization of ADC.

One of the notesthetic cooperation is the cooperation with Immunogen. Takeda has obtained the exclusive right to use the new ADC technology (including the new DNA effect IGN effective IGN) for up to two uninterrupted targets.Immunogen receives a prepaid payment from Takeda, which may get a milestone payment of up to $ 210 million, plus the franchise fee for commercial net sales of any ADC products.

The company also expanded the partnership with MERSANA Therapeutics to promote the development of Fleximer ADC, including XMT-1522 targeting HER2 to express tumors.This cooperation not only awarded Takeda's rights to the main candidates for MERSANA outside the United States and Canada, but also provides other targets with access to MERSANA's Fleximer ADC platform.

In addition, Takeda and Seagen emphasize the importance of Addris (Brentuximab Vedotin) to treat late Hodgkin lymphoma.Addris has been approved in more than 70 countries for the treatment of recurrence or refreshing Hodgkin lymphoma and systemic alien transgender lymphoma (SALCL).It is evaluated in more than 70 clinical trials, indicating that it has extensive potential in treating CD30 positive malignant tumors.

Recently, Takeda has also signed an exclusive license agreement with Innate Pharma to develop ADCs for cervical diarrhea.Takeda has agreed to pay 5 million US dollars to Innate Pharma. In terms of development, supervision and business milestones, it may reach up to $ 410 million.Essence

This transaction is part of the wider strategy of Takeda to solve the problem of cervling. This is the fourth measure since 2019, which aims to develop the disease.The agreement awarded Takeda's global exclusive rights to develop, develop, manufacture, and commercialize the global exclusive rights of the Innate antibody research, development, manufacturing, and commercial ADC, which marks a major measure to expand the ADC technology from the application of traditional oncology to autoimmune diseases such as citrus diarrhea.

2025cmc-china Pharmaceutical Expo • The booth is hot!